Zummo Jacqueline 4

What Happened Jacqueline Zummo, Protara Therapeutics' Chief Research & Development Officer, sold 22,598 shares on April 1, 2026, generating gross proceeds of approximately $118,865. The reported weighted-average price was $5.26 per share. This was a sale (not a purchase) and therefore generally considered routine insider selling rather than a direct bullish signal.

Key Details

• Transaction date: 2026-04-01; Form 4 filed: 2026-04-02 (appears timely).
• Shares sold: 22,598; weighted-average price: $5.26; total proceeds: ~$118,865.
• Price range: individual sales occurred between $5.25 and $5.31 (F2).
• Shares owned after transaction: not specified in the provided filing.
• Footnote F1: Sale occurred automatically under a Rule 10b5-1 trading plan established 12/31/2025.
• Footnote F2: Weighted-average price shown; reporting person can provide per-price breakdown on request.

Context The sale was executed under a pre-established 10b5-1 plan, indicating it was an automated, pre-planned disposition rather than an ad-hoc trade based on new information. For retail investors, purchases generally carry more informational weight than routine sales; a 10b5-1 sale is commonly used for liquidity or diversification and should not be interpreted on its own as a change in insider confidence.